All Articles

Clinical-stage biotech BioVie is advancing therapies targeting neuroinflammation and liver disease, with promising data from Alzheimer’s and Parkinson’s trials. The company is hosting an investor webinar to discuss progress.

A collaboration between Care Access and the Association of Black Cardiologists aims to expand access to vital heart health screenings and education, addressing a critical disparity in preventative care.

Harmony Biosciences initiates a Phase 1 trial for BP1.15205, an orexin 2 receptor agonist, aiming to address unmet needs in narcolepsy, idiopathic hypersomnia, and other central hypersomnolence disorders. Could this expand the company's sleep franchise?

GoLocker and Toys for Hospitalized Children team up to leverage secure package lockers as donation points, streamlining toy collection and bringing joy to young patients this holiday season.

LG’s new UltraFine evo 6K monitor isn’t just about resolution—it’s a connectivity leap forward. The industry’s first with Thunderbolt 5, it’s poised to redefine professional visual workflows.

A new TV ad campaign from Orion Metal Exchange aims to disrupt the often-opaque world of precious metals investing. The company emphasizes transparency, lower fees, and a customer-first approach, but does it deliver on its promises?

Fujifilm Sonosite’s new PIV Assist leverages artificial intelligence to enhance point-of-care ultrasound, promising quicker, more accurate peripheral IV insertions and improved patient experiences. A deeper look at the tech & market.

The acquisition of Dream Residential REIT adds 3,300 units to Morgan Properties’ portfolio, reflecting a growing trend of private equity investment in workforce housing and cross-border real estate deals.

A new report reveals a dramatic rise in sophisticated cyberattacks fueled by artificial intelligence. Experts warn of a growing leadership awareness gap and a shift towards cybersecurity resilience.

A substantial funding round positions Olema Oncology for growth, validating the potential of its novel breast cancer therapies and benefiting from positive momentum in the SERD market.

Positive Phase 3 trial data signals potential for EyePoint Pharmaceuticals’ DURAVYU to revolutionize wet AMD treatment, offering patients a less frequent alternative to monthly injections and a significant market opportunity.

Rejuva Fresh receives expanded CE certification for its EMSTRONG platform, broadening its application beyond urinary incontinence to include treatment for sexual dysfunction. The company is poised to benefit from the growing ‘intimate wellness’ market.

The renewable energy company’s debt maneuvers, including a $750M bond offering, aim to optimize its capital structure and fund continued expansion despite a challenging market. Investors watch closely.

As Black Friday approaches, Wayfair is doubling down on verified deals and a vast selection, aiming to capture a slice of the booming home goods market. But can its strategy compete with Amazon and other retail giants?

European approval of a subcutaneous formulation of Keytruda promises faster, more flexible treatment for cancer patients. This move positions Merck as a leader in innovative drug delivery and expands access to a critical therapy.

As Canada's cannabis sector matures, Grow Up Vancouver 2026 will tackle critical issues of consolidation, technological advancements, and regional opportunities, shaping the future of the industry.

Positive PFS results for the Cactus Project highlight potential for low-cost production and a significant contribution to domestic copper supply amid growing demand for critical minerals.

La Mancha’s increased investment in Belo Sun Mining Corp. raises questions about potential takeover bids and the future of the Volta Grande Gold Project in Brazil. Is this a strategic play or a precursor to a larger consolidation?

Digital freight platform Freightos partners with regional carrier Pattaya Airways to streamline air cargo booking in Southeast Asia. The move aims to boost efficiency and capacity on key routes like Bangkok-Ho Chi Minh City.

Biotech firm Cellectis unveils promising non-viral gene editing process with significantly improved efficiency. Experts believe this technology could lower costs and broaden access to life-saving therapies.